WCG provides the functional data that informs treatment selection and clinical development.
CytoVantage 3D measures how living tumor cells respond to cancer therapies within intact cell clusters. This approach preserves tumor biology and enables direct observation of treatment response.
Measures real tumor response, including cell death and resistance.
Evaluates both single agents and drug combinations.
Ranks therapies based on observed activity.
Supports repeat testing as disease evolves.
CytoVantage 3D integrates cell biology, quantitative cytometry, and analytical modeling to generate a functional profile of an individual patient’s tumor.
A viable tumor specimen is processed to preserve representative cancer cell populations.
Cells are exposed to a structured panel of cancer therapies and clinically relevant drug combinations.
Multiparametric assays measure cellular response across key biological pathways.
Results are integrated into a ranked response profile that identifies therapies demonstrating the strongest activity and highlights potential resistance.
No. Genetic and molecular tests identify mutations that may suggest sensitivity or resistance to treatment. WCG Precision Therapy measures functional response directly by observing how living tumor cells react to therapies. The two approaches can be complementary.
Testing requires a fresh, viable specimen with adequate cellularity. Yield and tumor heterogeneity may affect feasibility or scope.
Panels reflect clinical context and practicality. Not every agent can be tested, and clinical judgment remains essential.
No. CytoVantage 3D is a decision-support tool. Results are interpreted by clinicians within each patient’s broader medical picture.